CRISPR Therapeutics Announces Exclusive License of Lipid Nanoparticle Technologies Developed at MIT – Nasdaq
|
CRISPR Therapeutics Announces Exclusive License of Lipid Nanoparticle Technologies Developed at MIT
Nasdaq BASEL, Switzerland and CAMBRIDGE, Mass., May 08, 2017 (GLOBE NEWSWIRE) — CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases today announced … Crispr Therapeutics AG (CRSP) Insider Samarth Kulkarni Sells 11615 Shares |
